The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Abstract
IMPORTANCE: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. OBJECTIVE: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. EXPOSURE: Ipilimumab therapy. MAIN OUTCOMES AND MEASURES: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. RESULTS: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Possible risk factors for ICI-related hepatotoxicity include organ transplantation, comorbidity with autoimmune disease, history of ICI-induced irAEs, high doses of ICIs (particularly cytotoxic T-lymphocyte antigen 4 inhibitors), combination therapy with multiple ICIs, or a combination of an ICI with targeted therapy [165][166][167].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [165]
In the citing paper
“Incidence of endocrine events varies based on type of ICI used (see Figure 2).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“hypophysitis or hypopituitarism occurs in up to 10% of patients who receive anti-CTLA-4 based therapy (either with ipilimumab monotherapy, and slightly more commonly with combination CTLA-4/PD-1 blockade).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Cited by
Sorted by citations
Items 401–500 of 639
Reschke, R., Budde, P. I., Zucht, H., Mangana, J., Dummer, R., Pfoehler, C., Wistuba‐Hamprecht, K., Weide, B., Hakim‐Meibodi, L., Meier, F. E., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013814 · Cited by 10
Self-citationRogiers, A., Dimitriou, F., Lobón, I., Harvey, C., Vergara, I. A., da Silva, I. P., Lo, S., Scolyer, R. A., Carlino, M. S., Menzies, A. M., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113506 · Cited by 10
Self-citationAsao, T., Shukuya, T., Uemura, K., Kitadai, R., Yamamoto, G., Mouri, A., Tamaoka, M., Imai, R., Tsukita, Y., Isobe, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107894 · Cited by 10
Li, S. H., Townes, T., & Na’ara, S. (2024) · Cancers · doi:10.3390/cancers16183118 · Cited by 11
The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
Agmon, I. N., Zadok, O. I. B., & Kornowski, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030865 · Cited by 10
Pacholczak‐Madej, R., Kosałka-Węgiel, J., Kuszmiersz, P., Mituś, J. W., Püsküllüoğlu, M., Grela-Wojewoda, A., Korkosz, M., & Bazan‐Socha, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064926 · Cited by 10
Klavdianou, K., Μελισσαρόπουλος, Κ., Filippopoulou, A., & Daoussis, D. (2021) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.32.3.218 · Cited by 10
Kujtan, L. A., Kancha, R. K., Gustafson, B., Douglass, L., Ward, C. R., Buzard, B., & Subramanian, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2029414 · Cited by 10
Skejoe, C., Hansen, A. S., Stengaard‐Pedersen, K., Junker, P., Hoerslev-Pedersen, K., Hetland, M. L., Oestergaard, M. Z., Greisen, S. R., Hvid, M., Deleuran, M. S., et al. (2022) · PubMed Central · Cited by 10
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Savino, A., Rossi, A., FAGIUOLI, S., Invernizzi, P., Gerussi, A., & Viganò, M. (2024) · Cancers · doi:10.3390/cancers17010076 · Cited by 9
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Burke, M., & Rashdan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720759 · Cited by 9
Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
Robles, V., Martínez‐Valle, F., & Borruel, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906098 · Cited by 9
Liu, M., Christ, L., Richters, A., & Özdemir, B. C. (2023) · Oncology Letters · doi:10.3892/ol.2023.13963 · Cited by 9
Benson, Z., Gordon, S. W., Nicolato, P., & Poklepovic, A. S. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/8095601 · Cited by 9
Chen, P., Chen, F., & Zhou, B. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s154258 · Cited by 9
Papouin, B., Mussini, C., Martin, E. D., & Guettier, C. (2018) · Annales de Pathologie · doi:10.1016/j.annpat.2018.07.005 · Cited by 9
Shah, M., Jizzini, M., Majzoub, I. E., Qdaisat, A. Z., Reyes‐Gibby, C. C., & Yeung, S. J. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_11_19 · Cited by 9
Narrative review of immunotherapy in thymic malignancies
Benítez, J. C., & Besse, B. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1222 · Cited by 9
Stellato, M., Procopio, G., Giorgi, U. D., Maruzzo, M., Bimbatti, D., Mennitto, A., Sbrana, A., Roviello, G., Casadei, C., Sepe, P., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03008-9 · Cited by 10
Bujoreanu, F. C., Bezman, L. B., Radaschin, D. S., Niculeț, E., Bobeică, C., Crăescu, M., Nadasdy, T., Jicman, D., Ardeleanu, V., Nwabudike, L. C., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10789 · Cited by 9
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
Schepisi, G., Brighi, N., Cursano, M. C., Gurioli, G., Ravaglia, G., Altavilla, A., Burgio, S. L., Testoni, S., Menna, C., Farolfi, A., et al. (2019) · Journal of Oncology · doi:10.1155/2019/7317964 · Cited by 9
Xu, Y., Cai, Y., Zu, J., Wang, X., Wang, Y., Sun, C., Guo, Y., Shao, G., Yang, Z., Qiu, S., et al. (2020) · Immunotherapy · doi:10.2217/imt-2019-0090 · Cited by 9
Recognition and management of the gastrointestinal and hepatic immune‐related adverse events
Tan, B., Li, Y., Xu, Y., Chen, M., Wang, M., & Qian, J. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13317 · Cited by 9
Snavely, A. R., Pérez-Torres, E. J., Weber, J. S., Sandigursky, S., & Thawani, S. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120275 · Cited by 9
Sorting Out the Complexities of Autoimmunity and Checkpoint Inhibitors: Not So Easy
Calabrese, L. H. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3079 · Cited by 9
Higgins, J. P., Trinh, A. V., Watson, M. L., Beardslee, T. J., Goyal, S., Kudchadkar, R. R., Pakkala, S., Waltuck, J., Momary, K. M., & Byers, K. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001863 · Cited by 8
Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8
Kochanek, C., Gilde, C., Zimmer, L., Ugurel, S., Meier, F. E., Utikal, J. S., Pföhler, C., Herbst, R. A., Haferkamp, S., Welzel, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113508 · Cited by 9
Immune Checkpoint Inhibitor-Induced Psoriasis
Pach, J. J., Mbonu, N., Bhullar, S., Cohen, J. M., & Leventhal, J. S. (2024) · Dermatologic Clinics · doi:10.1016/j.det.2024.02.012 · Cited by 8
Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis
Nwankwo, O. C., Lara-Salazar, F. M., Lara-Salazar, S., Abdulrahim, A. O., Chijioke, I., Singh, J., Koradia, I., Gomez, N. M., Prakash, R., Gopagoni, R., et al. (2024) · Cureus · doi:10.7759/cureus.68043 · Cited by 8
Menon, T., & Afzali, A. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00263-0 · Cited by 8
Cortellini, A., Parisi, A., Fargnoli, M. C., Cannita, K., Irelli, A., Porzio, G., Martinazzo, C., & Ficorella, C. (2018) · Case Reports in Oncological Medicine · doi:10.1155/2018/2783917 · Cited by 8
Yamada, T., Masuda, T., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Miyamoto, S., Nakashima, T., Iwamoto, H., Hirata, S., Fujitaka, K., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3018-19 · Cited by 8
A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
Kageyama, S., Yamaguchi, S., Ito, S., Suehara, Y., Saito, T., Akaike, K., Miura, K., & Kato, S. (2016) · International Cancer Conference Journal · doi:10.1007/s13691-016-0256-8 · Cited by 8
Toxicities and outcomes: Do steroids matter?
Johnson, D. B. (2018) · Cancer · doi:10.1002/cncr.31627 · Cited by 8
Self-citationMallardo, D., Fordellone, M., Ottaviano, M., Marano, G., Vitale, M. G., Mallardo, M., Capasso, M., Cristofaro, T. D., Capone, M., Meinardi, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212439 · Cited by 7
Alatawi, A. D., Alaqyl, A. B., Alalawi, R. J., Alqarni, R. S., Sufyani, R. A., Alqarni, G. S. M., Alqarni, R. S., Albalawi, J. H., Alsharif, R. A., Alatawi, G. I., et al. (2025) · Diseases · doi:10.3390/diseases13080230 · Cited by 7
Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders
Kumar, R., Chan, A. S., Bandikatla, S., Ranjan, S., & Ngo, P. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100864 · Cited by 7
Prada, L. R., Gavrancic, T., Cadena-Sanabria, M. O., Dumic, I., Bourgeois, K., King, R. L., & Yan, Y. (2023) · American Journal of Case Reports · doi:10.12659/ajcr.941789 · Cited by 7
Wang, R., Zeng, H., Shi, M., Wu, Y. H., Liu, Y., & Zhang, T. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03883-2 · Cited by 7
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Sriratana, P., & Norton, J. A. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170387 · Cited by 7
Rubin, S. J. S., Balabanis, T., Gubatan, J. M. B., & Habtezion, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i6.1787 · Cited by 7
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
Park, B. J., Lee, A., Ye, F., Turker, I., & Johnson, D. B. (2022) · BMC Cancer · doi:10.1186/s12885-022-10090-9 · Cited by 7
Self-citationRecent advances in the management of Hodgkin lymphoma
Villasboas, J. C., & Ansell, S. M. (2016) · F1000Research · doi:10.12688/f1000research.8301.1 · Cited by 7
Bhave, P., Pham, A., Gordon, A., & Moore, M. A. (2020) · Immunotherapy · doi:10.2217/imt-2019-0184 · Cited by 7
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease
Spagnoletti, A., Platania, M., Brambilla, M., Occhipinti, M. A., Canziani, L., Cabras, A. D., Provenzano, L., Leone, A. G., Ambrosini, P., & Prelaj, A. (2022) · Tumori Journal · doi:10.1177/03008916211067565 · Cited by 7
Microbiota and immune-related adverse events in cancer immunotherapy
Schneider, S. M., Fan, C., Wang, Y., Jenq, R. R., & Watowich, S. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00921-3 · Cited by 6
Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren
Koelzer, V. H., Glatz, K., Bubendorf, L., Weber, A., Gaspert, A., Cathomas, G., Lugli, A., Zippelius, A., Kempf, W., & Mertz, K. D. (2017) · Der Pathologe · doi:10.1007/s00292-017-0281-1 · Cited by 6
Laubli, H. P., Dirnhofer, S., & Zippelius, A. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2435-9 · Cited by 6
Hijikata, Y., Matsubara, Y., Ota, Y., Lim, L. A., Tani, K., Hirata, Y., & Yotsuyanagi, H. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3901-19 · Cited by 6
Sun, Y.-M., Li, W., Chen, Z., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651553 · Cited by 6
Thomas, A. R., Liu, C., Tong, Y. T., Tan, D., Altan, M., Siddiqui, B. A., Shatila, M., Khan, A., Thomas, A. S., & Wang, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04499-9 · Cited by 6
Nylander, A. N., Rowles, W. M., Poole, S. T., & Bove, R. M. (2024) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173241252563 · Cited by 6
Immune Interventions to Eliminate the HIV Reservoir
Hsu, D. C., & Ananworanich, J. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_70 · Cited by 6
Johnson, M. L., Pennell, N. A., & Borghaei, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201231 · Cited by 6
Zarkavelis, G., Mauri, D. N., Karassa, F. B., Kampletsas, E. O., Pentheroudakis, G. E., Papadaki, A., Mavroeidis, L., Ntellas, P., Gκoura, S., & Gazouli, I. (2020) · Współczesna Onkologia · doi:10.5114/wo.2020.94727 · Cited by 6
Checkpoint Molecules in Rheumatology—or the Benefits of Being Exhausted
Greisen, S. R., & Deleuran, B. W. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-00991-2 · Cited by 6
Immune Checkpoint Inhibitors in Special Populations
Shan, Q., & Lu, H. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036526 · Cited by 7
Ruiz, J. I., Singh, G., Erck, M., Geng, Y., Suarez-Almazor, M. E., & Lopez-Olivo, M. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275676 · Cited by 6
Management of the Cutaneous Adverse Effects of Antimelanoma Therapy
Liu, R. C., Consuegra, G., & Fernández‐Peñas, P. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0015 · Cited by 6
Antonuzzo, A., Calabrò, F., Quaglino, P., Roila, F., Sebastiani, G. D., Spina, F., Pasqualetti, G., Cortinovis, D. L., Tagliaferri, E., Peri, A., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0035 · Cited by 7
Immunologic adverse events from immune checkpoint therapy
Richter, M. D., Hughes, G. C., Chung, S. H., Ezeanuna, M., Singh, N., & Thompson, J. A. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101511 · Cited by 6
Immunotherapy of solid tumors: how safely treat the patients
Domagala-Kulawik, J. J., Leszek, P., Owczarek, W. D., Rawa, T., Stelmachowska‐Banaś, M., & Rutkowski, P. L. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15314 · Cited by 6
Improving diagnosis and management of primary brain tumors
Delattre, J. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000500 · Cited by 6
Yang, X., Karapetyan, L., & Kirkwood, J. M. (2021) · Annals of Internal Medicine · doi:10.7326/l21-0441 · Cited by 6
Ye, C., Nikolic, R. P. A., Choi, M. Y., Fifi-Mah, A. V., Graham, J., O’Neil, L. J., Kobza, A. O., Lau, K. C. K., Arreola, L. A. G., Pardo, J. P., et al. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-0481 · Cited by 6
Ye, C., Nikolic, R. P. A., Choi, M. Y., Fifi-Mah, A. V., Graham, J., O’Neil, L. J., Kobza, A. O., Lau, K. C. K., Arreola, L. A. G., Pardo, J. P., et al. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-0482 · Cited by 6
Bossi, P., & Lorini, L. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s2a170s · Cited by 5
Freitas, J. D. A. S., Bendicho, M. T., & Júnior, A. D. F. S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231171881 · Cited by 5
Jacquin-Porretaz, C., Nardin, C., Puzenat, E., Roche-Kubler, B., Aubin, F., Schillo, F., Meillet, L., Borot, S., Vuitton, L., Koch, S., et al. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.05.032 · Cited by 5
Pach, J., & Leventhal, J. S. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023046895 · Cited by 5
Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis
Kayashima, A., Shimozaki, K., Hirata, K., Mutaguchi, M., Takabayashi, K., Hayashi, Y., Hosoe, N., Ogata, H., Sujino, T., & Kanai∥, T. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01261-x · Cited by 5
Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients
Nicolatou‐Galitis, O., Psyrri, A. K., Tsoukalas, N., Galitis, E., Linardou, H., Galiti, D., Athansiadis, I., Kalapanida, D., Razis, E. D., Katirtzoglou, N., et al. (2023) · Oral · doi:10.3390/oral3010011 · Cited by 5
Clínica, G. D. T. D. S. B. D. O. (2017) · Brazilian Journal of Oncology · doi:10.1055/s-0044-1792178 · Cited by 5
Ju, A., Tang, J., Chen, S., Fu, Y., & Luo, Y. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.17.440259 · Cited by 5
Immunological landscape of solid cancer: Interplay between tumor and autoimmunity
Singh, A. K., Duddempudi, P. K., Kenchappa, D., Srivastava, N., & Amdare, N. P. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.04.002 · Cited by 4
de Torres, C. S., Araguás, E. T., Marmolejo, D. H., Hermida, J. M. U., Mejia, N. M. D., Baselga, P. M., Cahuayme, A. A. A. G., Catalan, L., González, M., Morales‐Barrera, R., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105000 · Cited by 4
Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis
Moreno-Cárdenas, A. B., Ros, J., Gil‐Vila, A., Datta, D., Fasani, R., Serna, G., Jimenez, J., Araguás, E. T., Viaplana, C., Lostes, J., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.10.018 · Cited by 4
Gao, J., Miao, J., Zhinan, C., & Zhu, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611692 · Cited by 4
Co-signaling Molecules in Neurological Diseases
Kivisäkk, P., & Khoury, S. J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_9 · Cited by 4
Li, Y., Wang, H., Guo, X., Zhou, J., Duan, L., Si, X., Zhang, L., Liu, X., Qian, J., & Zhang, L. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.10 · Cited by 4
Challenges of Toxicity Management in Immuno-Oncology
Andrews, S. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0079 · Cited by 4
Berghmans, T., Grigoriu, B. D., Jp, S., & Meert, A. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.11.007 · Cited by 4
Nicholson, M. C., Pavenski, K., & Trinkaus, M. A. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.03.001 · Cited by 4
Immunotherapy in Special and Rare Situations: A Brief Review
Srinivas, S., & Bajpai, J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-6 · Cited by 4
Hahn, A. W., Shah, A. Y., & Campbell, M. T. (2021) · Kidney Cancer · doi:10.3233/kca-210123 · Cited by 4
Lopez-Olivo, M. A., & Ruíz-Camps, I. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875910 · Cited by 6
Report on the 2018 Cancer, Autoimmunity, and Immunology Conference
Curran, C. S., Sommers, C. L., Young, H. A., Bourcier, K., Mancini, M., & Sharon, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900264 · Cited by 4
Yash, A. (2018) · Annals of Clinical Oncology · doi:10.31487/j.aco.2019.02.01 · Cited by 4
Maeda, T., Yanagi, T., Imafuku, K., Kitamura, S., Hata, H., Izumi, K., Ujiie, H., Iwata, H., & Shimizu, H. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13713 · Cited by 4
Trikalinos, N. A., Chatterjee, D., Winter, K., Powell, M. A., & Yano, M. (2020) · The Oncologist · doi:10.1002/onco.13525 · Cited by 4
Greisen, S. R., Kunder, R. S., & Deleuran, B. W. (2016) · Rheumatology · doi:10.1093/rheumatology/kew276 · Cited by 4
Checkpoint inhibitors and arthritis: seeking balance between victories and defeats
Moura, C. A., & Moura, C. G. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213866 · Cited by 4
The double edge of cancer immunotherapy
(2017) · Nature Medicine · doi:10.1038/nm.4286 · Cited by 4
Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors
O'Sullivan, M. L., Cannon, G. W., Sauer, B. C., Rojas, J., Kunkel, G. A., Walsh, J. A., Patel, S. A., Roul, P., Baker, J. F., England, B. R., et al. (2025) · Arthritis Care & Research · doi:10.1002/acr.25691 · Cited by 3
Mahroum, N., Elsalti, A., Alsharif, M., Jabri, A., & Ouban, A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104002 · Cited by 3
Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review
Ismail, H., & Hassan, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1789760 · Cited by 3
Zhang, M. L., Algarrahi, K., DiCarlo, J., Elvin-Ivey, A., Dougan, M. L., & Mino-Kenudson, M. A. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.05.011 · Cited by 3
Stecca, C., Chowdhury, D., Blais, N., Alimohamed, N. S., Wood, L. A., Canil, C. M., Eigl, B., Kulkarni, G. S., Black, P. C., Kassouf, W., et al. (2024) · Canadian Urological Association Journal · doi:10.5489/cuaj.8946 · Cited by 4
Davies, M. J., & Duffield, E. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.277-283 · Cited by 3
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J. M., Sosman, J. A., Long, G. V., & Clark, J. I.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- The University of Sydney (AU)
- Roswell Park Comprehensive Cancer Center (US)
- Rutgers Cancer Institute (US)
- University Hospital Heidelberg (DE)
- Westmead Hospital (AU)
- Loyola University Medical Center (US)
- Corresponding author
- Johnson, Douglas B.
- ORCID
- Johnson, Douglas B.
- Sullivan, Ryan J.
- Ott, Patrick A.
- Carlino, Matteo S.
- Khushalani, Nikhil I.
- Ye, Fei
- Guminski, Alexander
- Puzanov, Igor
- Lawrence, Donald P.
- Buchbinder, Elizabeth I.
- Spencer, Kristen
- Bender, Carolin
- Lee, Jenny
- Kaufman, Howard L.
- Menzies, Alexander M.
- Hassel, Jessica C.
- Mehnert, Janice M.
- Sosman, Jeffrey A.
- Long, Georgina V.
- Clark, Joseph I.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 2
- Issue
- 2
- Pages
- 234
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2193769500
- Cited by
- 642
- References
- 30
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 49 · 2023: 44 · 2022: 64 · 2021: 73 · 2020: 94 · 2019: 93 · 2018: 65 · 2017: 68 · 2016: 47
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K12 CA 0906525, K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, advanced melanoma, immune-related adverse events, immune-related colitis, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related dermatitis, immune checkpoint inhibitors, immunosuppressive therapy, rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Female, Humans, Male, Melanoma, Middle Aged, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Autoimmunity, Treatment Outcome, Risk Assessment, Patient Selection, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
